ARCHIVES

EORTC Places Same Number on Phase 2-3 Trials As In U.S.

This article is from The Cancer Letter archive.

Vol. 12 No. 48 | December 12, 1986

Download PDF Visit The Full Archive

Related Articles

Chaos In Congress Killed $20 Million Increase For NCI

December 19, 1980

FDA Approvals: Lymphoseek Label Updated to Include Head and Neck SCC

June 27, 2014

In Brief: Biomedical Panel Report Will Support Cancer Program, Targeted Research

January 16, 1976

Doctor Files Defamation Suit Against Former Patient, But Legal Action Triggers Adverse Events

April 20, 2012

Gulf Health Study Begun With $10 Million Each from NIH, BP

September 24, 2010

ODAC Recommends Approval Of Paxen; Will IVAX Break Into $1 Billion Market

September 26, 1997